GALR3 and neoplasm: In contrast, 63% of glioblastoma multiforme samples (WHO grade IV) and 50% of gliosarcomas (WHO grade IV) showed sparse GAL3-R-immunoreactivity (<1–7% of tumor cells; Figures 5C,F).